

Johnson & Johnson to Provide Latest Updates on Hepatitis C Treatment

Pierre Raboisson, Head of Medicinal Chemistry at Janssen, to make a keynote address at 16th annual Superbugs and Superdrugs summit

LONDON , UNITED KINGDOM, February 11, 2014 /EINPresswire.com/ -- SMI are pleased to announce that Pierre Raboisson, Head of Medicinal Chemistry at Janssen (Johnson & Johnson), will be making a keynote address at the industry established conference on [Superbugs & Superdrugs](#) taking place soon on 5th and 6th March in London, UK.

In recent months, The FDA approved a new drug from Johnson & Johnson (Olysio) for use in treating chronic hepatitis C infections. Currently more than 170 million people are estimated to be infected with the virus. Following on from this, Janssen's Head of Medicinal Chemistry will be

presenting attendees with a keynote address entitled: The Latest Treatment for Hepatitis C, Challenges and Opportunities. Highlights will include:

- Diseases leading from chronic HCV

“

Very good and engaging speakers

Merck

- Protease Inhibitor (boceprevir, telaprevir and simeprevir) based triple therapy with pegylated interferon and ribavirin
- New direct-acting antivirals
- Updates on interferon-free combination treatment regimens

Visit <http://www.superbugssuperdrugs.com> to view presentation details and the full speaker line-up for 2014

The 16th annual conference on Superbugs & Superdrugs is the focal point for everyone working in the market for infectious diseases. Attending provides a unique forum to engage with leading industry experts active in the field. With less than a month until the event takes place, those interested in attending can book online at www.superbugssuperdrugs.com

Superbugs & Superdrugs will aim to provide attendees tools in:

- Best Practices – Share ideas with industry leaders to identify cutting-edge developments including antibody based strategies as a new method to tackle antimicrobial resistance , pre-clinical developments and new treatments for infection and preventing infection
- Strategy – Aid your antibiotic drug research and hear case study driven presentations from leading pharmaceutical and regulatory KOLS including EFPIA, GSK, BARDA, the European Commission, Johnson & Johnson, Sanofi, MedImmune and Astellas



- Funding - Discover the latest Public/Private Partnerships to combat antimicrobial resistance both in the US and in Europe
- Industry - Learn about hot topics which include antimicrobial stewardship, nanoparticulate oligonucleotide antibacterials and alternative models for tackling antimicrobial resistance
- Join the Debate – Participate in a round table discussion led by the European Commission, EFPIA, BARDA, GSK and TranScrip partners on Antibiotic R&D funding.
- The Future - Look ahead into the European Antibiotic Recovery Plan and analyse global solutions.
- Peer to peer networking - Ample opportunity for discussion, including 2 morning coffee breaks, 2 networking lunches and 2 afternoon tea sessions. Make new contacts, meet old friends and immerse yourself in a universe of new insights.

Previous instalments in the Superbugs & Superdrugs series received positive feedback from the industry including:

"Very well organised conference." – GSK

"Good level of quality." – Janssen

"Very good and engaging speakers." – Merck

"Good topics, mix of research, clinical development and perspectives" - J&J

For further information visit www.superbugsuperdrugs.com

Superbugs and Superdrugs: A focus on antibacterials

5th & 6th March 2014

Holiday Inn Regents Park, London UK

www.superbugsuperdrugs.com

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.